Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 10/20 | 0.43 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 10/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | SIRT3 | Q9NTG7 | 6/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CPB1 | P15086 | 1/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16216473 | 0.88 | GLP1R (0.41) | SIRT1SIRT6EPHX1 | |
| SCHEMBL13498646 | 0.85 | EPHX1 (0.57) | SIRT1SIRT6EPHX1SIRT2CTSS | |
| SCHEMBL13498651 | 0.85 | EPHX1 (0.62) | SIRT1SIRT6EPHX1SIRT2CTSS | |
| SCHEMBL13498644 | 0.85 | EPHX1 (0.53) | SIRT1SIRT6EPHX1SIRT2CTSS | |
| SCHEMBL24431370 | 0.81 | SIRT1 (0.53) | SIRT1SIRT6EPHX1SIRT2SIRT3 | |
| SCHEMBL14262320 | 0.81 | SIRT1 (0.44) | SIRT1SIRT6EPHX1SIRT2CTSS | |
| SCHEMBL13498562 | 0.80 | SIRT1 (0.46) | SIRT1SIRT6EPHX1SIRT2CTSS | |
| SCHEMBL17722384 | 0.80 | SIRT1 (0.46) | SIRT1SIRT6EPHX1SIRT2CTSS | |
| SCHEMBL13901982 | 0.80 | CPB1 (0.46) | SIRT1SIRT6EPHX1CPB1CPB2 | |
| SCHEMBL14805675 | 0.80 | SIRT1 (0.46) | SIRT1SIRT6EPHX1SIRT2SIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383380-B2 | Segmented polymers and their conjugates | NEKTAR THERAPEUTICS (US) | 2013-02-26 | — | — | US | disclosed |
| US-20120027714-A1 | Segmented Polymers and Their Conjugates | NEKTAR THERAPEUTICS (US) | 2012-02-02 | — | — | US | disclosed |
| US-8084572-B2 | Segmented polymers and their conjugates | NEKTAR THERAPEUTICS (US) | 2011-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120027714-A1 | Segmented Polymers and Their Conjugates | EPCAM, CD44, ECPAS | SIRT1 4051/4885SIRT6 4292/4885EPHX1 1395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.